{"id":11471,"date":"2025-07-26T17:26:08","date_gmt":"2025-07-26T15:26:08","guid":{"rendered":"https:\/\/valintermed.com\/?p=11471"},"modified":"2025-07-26T17:26:08","modified_gmt":"2025-07-26T15:26:08","slug":"gemoliticheskaya-anemiya","status":"publish","type":"post","link":"https:\/\/valintermed.com\/en\/medlibrary\/gemolitic-anemia\/","title":{"rendered":"Hemolytic anemia"},"content":{"rendered":"
<\/div>\n

Hemolytic anemia is a group of diseases characterized by accelerated destruction of red blood cells, which leads to a decrease in their number in the blood and, as a consequence, to anemia. Under normal conditions, the life of red blood cells is about 120 days, but with hemolytic anemia, this process is significantly accelerated, which can be caused by both autoimmune mechanisms and external factors. Clinical manifestations of the disease include fatigue, pale skin, tachycardia and jaundice, which is associated with the accumulation of bilirubin and a decrease in the oxygen capacity of the blood. Treatment of hemolytic anemia requires a comprehensive approach, including eliminating the cause of the disease and supportive therapy.<\/p>\n

\n
\n

Content<\/p>\nToggle<\/span><\/path><\/svg><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n